Answers are grounded in this paper and cite their sources.
Severe TEAEs are uncommon across Lu-PSMA, Ac-PSMA, and 223-Radium therapies. Still, monitoring and managing specific toxicities to optimize the safety and tolerability of these therapies in clinical practice is mandatory, especially concerning xerostomia in Ac-PSMA therapy.
No takes yet. Share an insight, caveat, or question.
Ventura et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: